$AQST
Aquestive Therapeutics, Inc. Stock $aqst

$aqst Overview Financials Valuation SEC Filings Company Website

2022 Q3 Form 10-Q Financial Statement

#000162828022020244 Filed on August 02, 2022

Income Statement

Concept	2022 Q3	2022 Q2	2022 Q1
Revenue	$11.46M	$13.27M	$12.27M
YoY Change	-13.73%	-13.55%	10.32%
Cost Of Revenue	$4.625M	$5.242M	$4.214M
YoY Change	5.11%	17.38%	52.85%
Gross Profit	$6.838M	$8.023M	$8.056M
YoY Change	-23.06%	-26.25%	-3.69%
Gross Profit Margin	59.65%	60.48%	65.66%
Selling, General & Admin	$12.46M	$15.59M	$13.02M
YoY Change	2.72%	18.68%	-1.59%
% of Gross Profit	182.2%	194.28%	161.63%
Research & Development	$3.232M	$5.198M	$4.773M
YoY Change	-31.61%	21.96%	30.45%
% of Gross Profit	47.27%	64.79%	59.25%
Depreciation & Amortization	$557.0K	$655.0K	$714.0K
YoY Change	-23.07%	-10.03%	-3.9%
% of Gross Profit	8.15%	8.16%	8.86%
Operating Expenses	$15.69M	$20.79M	$17.79M
YoY Change	-6.91%	19.48%	5.35%
Operating Profit	-$8.853M	-$12.76M	-$9.738M
YoY Change	11.11%	95.83%	14.23%
Interest Expense	$1.649M	$1.635M	$1.618M
YoY Change	-40.83%	-40.7%	-41.4%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$12.54M	-$16.30M	-$13.22M
YoY Change	-13.87%	31.82%	-9.9%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$12.54M	-$16.30M	-$13.22M
YoY Change	-13.87%	31.82%	-9.9%
Net Earnings / Revenue	-109.36%	-122.89%	-107.74%
Basic Earnings Per Share	-$0.23	-$0.36	-$0.32
Diluted Earnings Per Share	-$0.23	-$0.36	-$0.32
COMMON SHARES
Basic Shares Outstanding	53.35M shares	45.46M shares	41.47M shares
Diluted Shares Outstanding	53.42M shares	45.46M shares	41.47M shares

Balance Sheet

Concept	2022 Q3	2022 Q2	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$18.65M	$17.70M	$14.74M
YoY Change	-40.16%	-48.31%	-46.41%
Cash & Equivalents	$18.65M	$17.70M	$14.74M
Short-Term Investments
Other Short-Term Assets	$1.976M	$1.637M	$3.324M
YoY Change	-22.2%	-8.95%	-15.63%
Inventory	$6.725M	$5.008M	$4.629M
Prepaid Expenses
Receivables	$10.74M	$19.17M	$19.90M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$38.09M	$43.51M	$42.59M
YoY Change	-24.14%	-14.69%	-4.18%
LONG-TERM ASSETS
Property, Plant & Equipment	$4.284M	$4.569M	$4.496M
YoY Change	-17.57%	-21.1%	-28.4%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$5.893M	$5.897M	$6.886M
YoY Change	-14.66%	-14.64%	-12.11%
Total Long-Term Assets	$13.76M	$12.81M	$13.94M
YoY Change	-8.78%	-19.35%	-20.23%
TOTAL ASSETS
Total Short-Term Assets	$38.09M	$43.51M	$42.59M
Total Long-Term Assets	$13.76M	$12.81M	$13.94M
Total Assets	$51.85M	$56.31M	$56.53M
YoY Change	-20.6%	-15.8%	-8.71%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$11.07M	$8.887M	$8.496M
YoY Change	78.15%	9.72%	27.05%
Accrued Expenses	$7.733M	$7.042M	$4.868M
YoY Change	1.43%	6.97%	-23.59%
Deferred Revenue	$774.0K	$1.599M	$1.599M
YoY Change	0.91%	149.07%	265.9%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$14.23M	$9.750M	$6.563M
YoY Change	84.14%	89.32%	70.03%
Total Short-Term Liabilities	$36.56M	$29.64M	$24.18M
YoY Change	46.01%	28.66%	20.62%
LONG-TERM LIABILITIES
Long-Term Debt	$38.68M	$43.82M	$47.68M
YoY Change	18.37%	28.62%	39.46%
Other Long-Term Liabilities	$2.159M	$2.379M	$1.862M
YoY Change	19.28%	34.41%	5.74%
Total Long-Term Liabilities	$2.159M	$2.379M	$1.862M
YoY Change	19.28%	34.41%	5.74%
TOTAL LIABILITIES
Total Short-Term Liabilities	$36.56M	$29.64M	$24.18M
Total Long-Term Liabilities	$2.159M	$2.379M	$1.862M
Total Liabilities	$159.7M	$152.7M	$149.7M
YoY Change	27.08%	26.54%	31.61%
SHAREHOLDERS EQUITY
Retained Earnings	-$298.9M	-$286.3M	-$270.0M
YoY Change	31.16%	34.24%	34.38%
Common Stock	$54.00K	$53.00K	$41.00K
YoY Change	35.0%	35.9%	13.89%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$107.8M	-$96.36M	-$93.14M
YoY Change
Total Liabilities & Shareholders Equity	$51.85M	$56.31M	$56.53M
YoY Change	-20.6%	-15.8%	-8.71%

Cashflow Statement

Concept	2022 Q3	2022 Q2	2022 Q1
OPERATING ACTIVITIES
Net Income	-$12.54M	-$16.30M	-$13.22M
YoY Change	-13.87%	31.82%	-9.9%
Depreciation, Depletion And Amortization	$557.0K	$655.0K	$714.0K
YoY Change	-23.07%	-10.03%	-3.9%
Cash From Operating Activities	$2.809M	-$6.562M	-$14.48M
YoY Change	-130.99%	274.33%	2.73%
INVESTING ACTIVITIES
Capital Expenditures	-$1.717M	-$677.0K	$104.0K
YoY Change	1968.67%	243.65%	0.97%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$1.717M	-$677.0K	-$104.0K
YoY Change	1968.67%	243.65%	0.97%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-138.0K	10.20M	$1.298M
YoY Change	-102.27%	17.39%	-86.88%
NET CHANGE
Cash From Operating Activities	2.809M	-6.562M	-$14.48M
Cash From Investing Activities	-1.717M	-677.0K	-$104.0K
Cash From Financing Activities	-138.0K	10.20M	$1.298M
Net Change In Cash	954.0K	2.959M	-$13.29M
YoY Change	-131.07%	-56.08%	208.38%
FREE CASH FLOW
Cash From Operating Activities	$2.809M	-$6.562M	-$14.48M
Capital Expenditures	-$1.717M	-$677.0K	$104.0K
Free Cash Flow	$4.526M	-$5.885M	-$14.59M
YoY Change	-150.39%	278.21%	2.72%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Central Index Key EntityCentralIndexKey	0001398733
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Entity Address Address Line1 EntityAddressAddressLine1	30 Technology Drive
	dei	Entity Address City Or Town EntityAddressCityOrTown	Warren
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2022-06-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-38599
	dei	Entity Registrant Name EntityRegistrantName	Aquestive Therapeutics, Inc.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Address State Or Province EntityAddressStateOrProvince	NJ
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	07059
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	82-3827296
	dei	City Area Code CityAreaCode	908
	us-gaap	Variable Lease Cost VariableLeaseCost	223000	usd
	dei	Local Phone Number LocalPhoneNumber	941-1900
	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
	dei	Trading Symbol TradingSymbol	AQST
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	53350654	shares
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	17695000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	28024000	usd
CY2022Q2	aqst	Trade And Other Receivables Net TradeAndOtherReceivablesNet	19165000	usd
CY2021Q4	aqst	Trade And Other Receivables Net TradeAndOtherReceivablesNet	12120000	usd
CY2022Q2	us-gaap	Inventory Net InventoryNet	5008000	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	4038000	usd
CY2022Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1637000	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3077000	usd
CY2022Q2	us-gaap	Assets Current AssetsCurrent	43505000	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	47259000	usd
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4569000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5055000	usd
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2314000	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2725000	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	25000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	51000	usd
CY2022Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	5897000	usd
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	6903000	usd
CY2022Q2	us-gaap	Assets Assets	56310000	usd
CY2021Q4	us-gaap	Assets Assets	61993000	usd
CY2022Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	8887000	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	8314000	usd
CY2022Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	7042000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	8736000	usd
CY2022Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	913000	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	899000	usd
CY2022Q2	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	1599000	usd
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	765000	usd
CY2022Q2	aqst	Transfer Of Financial Assets Accounted For As Sales Amount Derecognized Current TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognizedCurrent	1445000	usd
CY2021Q4	aqst	Transfer Of Financial Assets Accounted For As Sales Amount Derecognized Current TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognizedCurrent	1225000	usd
CY2022Q2	us-gaap	Loans Payable Current LoansPayableCurrent	9750000	usd
CY2021Q4	us-gaap	Loans Payable Current LoansPayableCurrent	2025000	usd
CY2022Q2	us-gaap	Liabilities Current LiabilitiesCurrent	29636000	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	21964000	usd
CY2022Q2	us-gaap	Long Term Loans Payable LongTermLoansPayable	43821000	usd
CY2021Q4	us-gaap	Long Term Loans Payable LongTermLoansPayable	51551000	usd
CY2022Q2	aqst	Transfer Of Financial Assets Accounted For As Sales Amount Derecognized Noncurrent TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognizedNoncurrent	61839000	usd
CY2021Q4	aqst	Transfer Of Financial Assets Accounted For As Sales Amount Derecognized Noncurrent TransferOfFinancialAssetsAccountedForAsSalesAmountDerecognizedNoncurrent	59059000	usd
CY2022Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1502000	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1946000	usd
CY2022Q2	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	13490000	usd
CY2021Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	7122000	usd
CY2022Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2379000	usd
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2485000	usd
CY2022Q2	us-gaap	Liabilities Liabilities	152667000	usd
CY2021Q4	us-gaap	Liabilities Liabilities	144127000	usd
CY2022Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2021Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	15345000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	25535000	usd
CY2022Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	53343989	shares
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	53343989	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	41228736	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	41228736	shares
CY2022Q2	us-gaap	Common Stock Value CommonStockValue	53000	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	41000	usd
CY2022Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	189908000	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	174621000	usd
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-286318000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-256796000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	-96357000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-82134000	usd
CY2022Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	56310000	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	61993000	usd
CY2022Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	13265000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	26467000	usd
CY2022Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	5242000	usd
CY2021Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	4466000	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	9456000	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	7223000	usd
CY2022Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5198000	usd
CY2021Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4262000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	9971000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7921000	usd
CY2022Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	15587000	usd
CY2021Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	13134000	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	28608000	usd
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	26365000	usd
CY2022Q2	us-gaap	Costs And Expenses CostsAndExpenses	26027000	usd
CY2021Q2	us-gaap	Costs And Expenses CostsAndExpenses	21862000	usd
	us-gaap	Costs And Expenses CostsAndExpenses	48035000	usd
	us-gaap	Costs And Expenses CostsAndExpenses	41509000	usd
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-12762000	usd
CY2021Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-6517000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-22500000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-15042000	usd
CY2022Q2	us-gaap	Interest Expense InterestExpense	1635000	usd
CY2021Q2	us-gaap	Interest Expense InterestExpense	2757000	usd
	us-gaap	Interest Expense InterestExpense	3253000	usd
	us-gaap	Interest Expense InterestExpense	5518000	usd
CY2022Q2	aqst	Interest Expense Sale Of Future Revenues InterestExpenseSaleOfFutureRevenues	1937000	usd
CY2021Q2	aqst	Interest Expense Sale Of Future Revenues InterestExpenseSaleOfFutureRevenues	3466000	usd
	aqst	Interest Expense Sale Of Future Revenues InterestExpenseSaleOfFutureRevenues	3798000	usd
	aqst	Interest Expense Sale Of Future Revenues InterestExpenseSaleOfFutureRevenues	6800000	usd
CY2022Q2	aqst	Interest And Other Income Net InterestAndOtherIncomeNet	32000	usd
CY2021Q2	aqst	Interest And Other Income Net InterestAndOtherIncomeNet	373000	usd
	aqst	Interest And Other Income Net InterestAndOtherIncomeNet	29000	usd
	aqst	Interest And Other Income Net InterestAndOtherIncomeNet	321000	usd
CY2022Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-16302000	usd
CY2021Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-12367000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-29522000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-27039000	usd
CY2022Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2021Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-16302000	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-12367000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-29522000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-27039000	usd
CY2022Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-16302000	usd
CY2021Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-12367000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-29522000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-27039000	usd
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.36
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.36
CY2021Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.33
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.33
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.68
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.68
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.74
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.74
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	45462516	shares
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	45462516	shares
CY2021Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	37065300	shares
CY2021Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	37065300	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	43475198	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	43475198	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	36318437	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	36318437	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-82134000	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	913000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-13220000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	-93143000	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	15000	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2219000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-16302000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	-96357000	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-48497000	usd
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1507000	usd
CY2021Q1	us-gaap	Stockholders Equity Other StockholdersEquityOther	27000	usd
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-14672000	usd
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	-51798000	usd
CY2021Q2	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	76000	usd
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1710000	usd
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition	-4000	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-12367000	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	-53769000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-29522000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-27039000	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1394000	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1497000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	3132000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	3228000	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	109000	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	2388000	usd
	aqst	Interest Expense Sale Of Future Revenues Excluding Amortization InterestExpenseSaleOfFutureRevenuesExcludingAmortization	3722000	usd
	aqst	Interest Expense Sale Of Future Revenues Excluding Amortization InterestExpenseSaleOfFutureRevenuesExcludingAmortization	6729000	usd
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	161000	usd
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	125000	usd
	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	6949000	usd
	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	5392000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	970000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	378000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-2446000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-2532000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	574000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1011000	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-2021000	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-2971000	usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	7202000	usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	2667000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-21044000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-15853000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	781000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	297000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-781000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-297000	usd
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	2473000	usd
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	18505000	usd
	aqst	Proceeds From Issuance Private Offering ProceedsFromIssuancePrivateOffering	3805000	usd
	aqst	Proceeds From Issuance Private Offering ProceedsFromIssuancePrivateOffering	0	usd
	aqst	Proceeds From Issuance And Exercise Of Warrants ProceedsFromIssuanceAndExerciseOfWarrants	5878000	usd
	aqst	Proceeds From Issuance And Exercise Of Warrants ProceedsFromIssuanceAndExerciseOfWarrants	0	usd
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	15000	usd
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	76000	usd
	us-gaap	Payments Of Debt Extinguishment Costs PaymentsOfDebtExtinguishmentCosts	675000	usd
	us-gaap	Payments Of Debt Extinguishment Costs PaymentsOfDebtExtinguishmentCosts	0	usd
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	0	usd
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	4000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	11496000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	18577000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-10329000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	2427000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	28024000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	31807000	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	17695000	usd
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	34234000	usd
	us-gaap	Interest Paid Net InterestPaidNet	1609000	usd
	us-gaap	Interest Paid Net InterestPaidNet	3219000	usd
	aqst	Number Of Products Approved By Food And Drug Administration NumberOfProductsApprovedByFoodAndDrugAdministration	5	product
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	17695000	usd
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-286318000	usd
CY2022Q2	us-gaap	Other Receivables Gross Current OtherReceivablesGrossCurrent	3474000	usd
CY2021Q4	us-gaap	Other Receivables Gross Current OtherReceivablesGrossCurrent	3087000	usd
CY2022Q2	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	15089000	usd
CY2021Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	7887000	usd
CY2022Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	13265000	usd
CY2021Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	15345000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	25535000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	26467000	usd
CY2021Q4	aqst	Accounts Receivable Allowances And Accruals Trade And Other Receivables Net AccountsReceivableAllowancesAndAccrualsTradeAndOtherReceivablesNet	605000	usd
CY2022Q2	aqst	Trade And Other Receivables Net TradeAndOtherReceivablesNet	19165000	usd
CY2021Q4	aqst	Trade And Other Receivables Net TradeAndOtherReceivablesNet	12120000	usd
CY2022Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	13265000	usd
CY2021Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	15345000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	25535000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	26467000	usd
CY2022Q2	us-gaap	Accounts Receivable Gross AccountsReceivableGross	16240000	usd
CY2021Q4	us-gaap	Accounts Receivable Gross AccountsReceivableGross	9678000	usd
CY2022Q2	us-gaap	Other Receivables Gross Current OtherReceivablesGrossCurrent	3474000	usd
CY2021Q4	us-gaap	Other Receivables Gross Current OtherReceivablesGrossCurrent	3087000	usd
CY2022Q2	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	40000	usd
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	40000	usd
CY2022Q2	aqst	Accounts Receivable Allowances And Accruals Trade And Other Receivables Net AccountsReceivableAllowancesAndAccrualsTradeAndOtherReceivablesNet	509000	usd
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	40000	usd
CY2020Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	40000	usd
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	usd
CY2021	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	usd
	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	0	usd
	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	0	usd
CY2022Q2	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	40000	usd
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	40000	usd
CY2021Q4	aqst	Accounts Receivable Allowances And Accruals AccountsReceivableAllowancesAndAccruals	605000	usd
	aqst	Accounts Receivable Allowances Provision Reversal Related To Sales AccountsReceivableAllowancesProvisionReversalRelatedToSales	529000	usd
	aqst	Accounts Receivable Allowances Credits And Payments AccountsReceivableAllowancesCreditsAndPayments	625000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	843000	usd
CY2022Q2	aqst	Accounts Receivable Allowances And Accruals AccountsReceivableAllowancesAndAccruals	509000	usd
	aqst	Accounts Receivable Allowances Provision Reversal Related To Sales AccountsReceivableAllowancesProvisionReversalRelatedToSales	529000	usd
CY2022Q2	aqst	Accounts Receivable Allowances And Accruals Trade And Other Receivables Net AccountsReceivableAllowancesAndAccrualsTradeAndOtherReceivablesNet	509000	usd
CY2022Q2	aqst	Accounts Receivable Allowances And Accruals Accounts Payable And Accrued Expenses AccountsReceivableAllowancesAndAccrualsAccountsPayableAndAccruedExpenses	2656000	usd
CY2021Q4	aqst	Accounts Receivable Allowances And Accruals Trade And Other Receivables Net AccountsReceivableAllowancesAndAccrualsTradeAndOtherReceivablesNet	605000	usd
CY2021Q4	aqst	Accounts Receivable Allowances And Accruals Accounts Payable And Accrued Expenses AccountsReceivableAllowancesAndAccrualsAccountsPayableAndAccruedExpenses	2224000	usd
CY2020Q4	aqst	Days Required Prior To Written Notice DaysRequiredPriorToWrittenNotice	P180D
CY2022Q2	aqst	Pro Rata Portion Of Target Bonus ProRataPortionOfTargetBonus	279863	usd
CY2022Q2	aqst	Cash Payment Representing90 Days Of Base Pay CashPaymentRepresenting90DaysOfBasePay	150000	usd
CY2022Q2	aqst	Days Of Base Pay DaysOfBasePay	90	day
CY2022Q2	us-gaap	Severance Costs1 SeveranceCosts1	262500	usd
CY2022Q2	aqst	Severance Period SeverancePeriod	P18M
CY2022Q2	aqst	Coverage Duration CoverageDuration	P18M
CY2022Q2	aqst	Consulting Fee ConsultingFee	10000	usd
	us-gaap	Depreciation Depreciation	1471000	usd
CY2022Q2	us-gaap	Variable Lease Cost VariableLeaseCost	127000	usd
CY2021Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	430000	usd
CY2022Q2	us-gaap	Inventory Raw Materials InventoryRawMaterials	1524000	usd
CY2021Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	1442000	usd
CY2022Q2	aqst	Inventory Packing Material Gross InventoryPackingMaterialGross	1795000	usd
CY2021Q4	aqst	Inventory Packing Material Gross InventoryPackingMaterialGross	1414000	usd
CY2022Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	1689000	usd
CY2021Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	1182000	usd
CY2022Q2	us-gaap	Inventory Net InventoryNet	5008000	usd
CY2021Q4	us-gaap	Inventory Net InventoryNet	4038000	usd
CY2022Q2	aqst	Number Of Operating Leases NumberOfOperatingLeases	3	lease
CY2022Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	424000	usd
CY2022Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	45695000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	44915000	usd
CY2022Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	41126000	usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	39860000	usd
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4569000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5055000	usd
CY2022Q2	us-gaap	Depreciation Depreciation	655000	usd
CY2021Q2	us-gaap	Depreciation Depreciation	728000	usd
	us-gaap	Depreciation Depreciation	1369000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	863000	usd
CY2021Q2	us-gaap	Variable Lease Cost VariableLeaseCost	116000	usd
	us-gaap	Variable Lease Cost VariableLeaseCost	235000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	649000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	945000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	565000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	565000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	424000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	3148000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	733000	usd
CY2022Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	2415000	usd
CY2020Q4	aqst	Premiums Paid Early Retirement Of Debt PremiumsPaidEarlyRetirementOfDebt	2250000	usd
	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	2909000	usd
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	45462516	shares
CY2022Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	2867000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	2867000	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	2842000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	2816000	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	25000	usd
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	51000	usd
CY2022Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	12000	usd
CY2021Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	12000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	25000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	25000	usd
CY2022Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	25000	usd
CY2022Q2	aqst	Cumulative Royalty Receivable CumulativeRoyaltyReceivable	5000000	usd
CY2021Q4	aqst	Cumulative Royalty Receivable CumulativeRoyaltyReceivable	6000000	usd
CY2022Q2	us-gaap	Other Assets Miscellaneous Noncurrent OtherAssetsMiscellaneousNoncurrent	897000	usd
CY2021Q4	us-gaap	Other Assets Miscellaneous Noncurrent OtherAssetsMiscellaneousNoncurrent	903000	usd
CY2022Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	5897000	usd
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	6903000	usd
	aqst	Number Of Guaranteed Royalty Payments NumberOfGuaranteedRoyaltyPayments	8	payment
	aqst	Premiums Paid Early Retirement Of Debt PremiumsPaidEarlyRetirementOfDebt	2250000	usd
CY2022Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3928000	usd
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	5965000	usd
CY2022Q2	us-gaap	Taxes Payable Current TaxesPayableCurrent	267000	usd
CY2021Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	349000	usd
CY2022Q2	aqst	Accounts Receivable Allowances And Accruals Accounts Payable And Accrued Expenses AccountsReceivableAllowancesAndAccrualsAccountsPayableAndAccruedExpenses	2656000	usd
CY2021Q4	aqst	Accounts Receivable Allowances And Accruals Accounts Payable And Accrued Expenses AccountsReceivableAllowancesAndAccrualsAccountsPayableAndAccruedExpenses	2224000	usd
CY2022Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	191000	usd
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	198000	usd
CY2022Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	7042000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	8736000	usd
CY2019Q3	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	2000000	shares
CY2019Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.001
CY2019Q3	aqst	Net Proceeds From Issuance Of Initial Notes Warrants And First Offer Rights NetProceedsFromIssuanceOfInitialNotesWarrantsAndFirstOfferRights	66082000	usd
CY2022Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	0	usd
CY2022Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	18025000	usd
CY2022Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	21888000	usd
CY2022Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	11587000	usd
CY2022Q2	us-gaap	Long Term Debt LongTermDebt	51500000	usd
CY2021Q4	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	13822000	usd
	aqst	Class Of Warrant Or Right Warrants Exercised ClassOfWarrantOrRightWarrantsExercised	0	shares
	aqst	Class Of Warrant Or Right Warrants Exercised ClassOfWarrantOrRightWarrantsExercised	0	shares
CY2022Q2	aqst	Shares Of Common Stock Entitled To Purchasers By Pre Funded Warrants SharesOfCommonStockEntitledToPurchasersByPreFundedWarrants	4000000	shares
CY2022Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.0001
CY2022Q2	aqst	Shares Of Common Stock To Be Purchased By Common Stock Warrants SharesOfCommonStockToBePurchasedByCommonStockWarrants	8850000	shares
CY2021Q4	aqst	Liabilities Sale Of Future Royalties LiabilitiesSaleOfFutureRoyalties	60284000	usd
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	101000	usd
	aqst	Interest Expense Sale Of Future Revenues Excluding Amortization InterestExpenseSaleOfFutureRevenuesExcludingAmortization	3722000	usd
CY2022Q2	aqst	Liabilities Sale Of Future Royalties Current LiabilitiesSaleOfFutureRoyaltiesCurrent	1445000	usd
CY2022Q2	aqst	Liabilities Sale Of Future Royalties LiabilitiesSaleOfFutureRoyalties	63284000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-16302000	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-12367000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-29522000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-27039000	usd
CY2021Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	37065300	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	43475198	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	43475198	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	36318437	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	36318437	shares
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.36
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.36
CY2021Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.33
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.33
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.68
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.68
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.74
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.74
CY2022Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2221000	usd
CY2021Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1721000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3134000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3228000	usd
CY2022Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2221000	usd
CY2021Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1721000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3134000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3228000	usd
CY2019Q1	aqst	Percent Of Fair Value Of Shares Employees Purchase PercentOfFairValueOfSharesEmployeesPurchase	0.85
CY2022Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2021Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-16302000	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-12367000	usd
CY2022Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2021Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
	us-gaap	Net Income Loss NetIncomeLoss	-29522000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-27039000	usd

Files In Submission

Name	View Source	Status
0001628280-22-020244-index-headers.html	Edgar Link	pending
0001628280-22-020244-index.html	Edgar Link	pending
0001628280-22-020244.txt	Edgar Link	pending
0001628280-22-020244-xbrl.zip	Edgar Link	pending
aqst-06302022ex311.htm	Edgar Link	pending
aqst-06302022ex312.htm	Edgar Link	pending
aqst-06302022ex321.htm	Edgar Link	pending
aqst-06302022ex322.htm	Edgar Link	pending
aqst-20220630.htm	Edgar Link	pending
aqst-20220630.xsd	Edgar Link	pending
aqst-20220630_cal.xml	Edgar Link	unprocessable
aqst-20220630_def.xml	Edgar Link	unprocessable
aqst-20220630_htm.xml	Edgar Link	completed
aqst-20220630_lab.xml	Edgar Link	unprocessable
aqst-20220630_pre.xml	Edgar Link	unprocessable
danbarber2022ceoemployme.htm	Edgar Link	pending
danbarber2022ceoemployme001.jpg	Edgar Link	pending
danbarber2022ceoemployme002.jpg	Edgar Link	pending
danbarber2022ceoemployme003.jpg	Edgar Link	pending
danbarber2022ceoemployme004.jpg	Edgar Link	pending
danbarber2022ceoemployme005.jpg	Edgar Link	pending
danbarber2022ceoemployme006.jpg	Edgar Link	pending
danbarber2022ceoemployme007.jpg	Edgar Link	pending
danbarber2022ceoemployme008.jpg	Edgar Link	pending
danbarber2022ceoemployme009.jpg	Edgar Link	pending
danbarber2022ceoemployme010.jpg	Edgar Link	pending
danbarber2022ceoemployme011.jpg	Edgar Link	pending
danbarber2022ceoemployme012.jpg	Edgar Link	pending
danbarber2022ceoemployme013.jpg	Edgar Link	pending
danbarber2022ceoemployme014.jpg	Edgar Link	pending
danbarber2022ceoemployme015.jpg	Edgar Link	pending
danbarber2022ceoemployme016.jpg	Edgar Link	pending
danbarber2022ceoemployme017.jpg	Edgar Link	pending
danbarber2022ceoemployme018.jpg	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$AQST
Aquestive Therapeutics, Inc. Stock $aqst

2022 Q3 Form 10-Q Financial Statement

#000162828022020244 Filed on August 02, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AQST Aquestive Therapeutics, Inc. Stock $aqst

2022 Q3 Form 10-Q Financial Statement

#000162828022020244 Filed on August 02, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AQST
Aquestive Therapeutics, Inc. Stock $aqst